on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies
OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York. This agreement relates to patents relating to CAR (Chimeric Antigen Receptor) cell therapies targeting cancers expressing the Interleukin-7 Receptor (IL-7R), in particular Acute Lymphoblastic Leukemia.
Under the agreement, MSK will be responsible for research, development and commercialization activities. Potential revenues will be shared with OSE Immunotherapeutics. Nicolas Poirier, Managing Director of OSE Immunotherapeutics, is delighted with this collaboration with a world leader in oncology.
Dr. Prasad S. Adusumilli, Principal at MSK, expressed his eagerness to begin clinical trials of CARs targeting IL-7R. This agreement stems from an initial collaboration aimed at exploring the potential of a non-antagonistic monoclonal antibody to IL-7R.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news